Boston Scientific second-quarter sales reach $5.442 billion
Share
- Boston Scientific reported second-quarter net sales of $5.442 billion, a 7.5% year-over-year increase.
- The company completed a $2 billion share repurchase and posted an adjusted EPS of $0.86.
- The company stated its $1.5 billion MiRus investment will support its ongoing medical technology portfolio expansion.
Boston Scientific (NYSE:BSX) reported second-quarter net sales of $5.442 billion, representing a 7.5% year-over-year increase.
This growth was driven by MedSurg expanding 5.9% alongside an 8.3% reported rise in the Cardiovascular segment.
The company posted an adjusted earnings per share of $0.86, beating its expected $0.82 to $0.84 range.
Operating income rose to $1.178 billion despite the company recording $76 million in litigation-related net charges.
Following the announcement, Boston Scientific's share price was up at $46.79.
The business completed a $2 billion share repurchase and invested $1.5 billion for a stake in MiRus.
Boston Scientific stated its full-year 2026 guidance anticipates net sales growth between 5.5% and 6.5%.
